TERMINALLY EXHAUSTED CD8+ TUMOR-INFILTRATING LYMPHOCYTES AND M2-LIKE MACROPHAGES AS BIOMARKERS OF RESISTANCE TO FIRST-LINE ANTI-PD-1 THERAPY IN METASTATIC RCC.

Brigham & Womens Hospital Inc

Investigators